Results 131 to 140 of about 21,829 (156)

Reply to Feng, "Recalculation of inhibitor concentration fold-changes for CMY-219: comments on a recent article about CMY-219 conferring resistance to ceftazidime-avibactam". [PDF]

Antimicrob Agents Chemother
Jousset AB, Girlich D, Oueslati S, Birer A, Delaval A, Guyot C, Rezzoug I, Emeraud C, Naas T, Bonnin RA, Dortet L.   +10 more
europepmc   +1 more source

Ceftazidime-Avibactam/Aztreonam Combination for the Treatment of Carbapenem-resistant Klebsiella pneumoniae-induced Osteomyelitis: A Case Series with Review of Literature. [PDF]

J Orthop Case Rep
Gupta A, Chaudhari H, Kumar R, Mishra AK, Aggarwal N, Saran A.   +5 more
europepmc   +1 more source

Fitness cost of ceftazidime-avibactam resistance acquisition in carbapenem-resistant hypervirulent Klebsiella pneumoniae. [PDF]

BMC Microbiol
Huang M, Xiao SP, Zeng QH, Guo HM, Liu YT, Wei DD, Kang XH.   +6 more
europepmc   +1 more source

Cefiderocol Heteroresistance in NDM-Producing Enterobacterales: A Complex Polymicrobial Infection Successfully Salvaged With Ceftazidime-Avibactam Plus Aztreonam. [PDF]

Am J Case Rep
Nuaimi M, Cirillo J, Usbosy S, Egan D, Kovacich A, Madruga M, Carlan SJ.   +6 more
europepmc   +1 more source

Comparison of agar-based methodologies to broth disc elution for the detection of aztreonam susceptibility in the presence of ceftazidime-avibactam. [PDF]

Microbiol Spectr
Sandstrom TS, Banete A, Kanyua A, Davis KM, Poutanen SM.   +4 more
europepmc   +1 more source

Ceftazidime/Avibactam Monotherapy Versus Other Antibiotics: Where Do We Stand? [PDF]

Pathogens
Vougiouklakis G, Tsioutis C, Vasileiadi N, Alexakis K, Spernovasilis N, Agouridis AP.   +5 more
europepmc   +1 more source

Comparison of laboratory-developed methods for aztreonam plus ceftazidime-avibactam antimicrobial susceptibility testing for metallo-beta-lactamase-producing Enterobacterales. [PDF]

J Clin Microbiol
Bhatnagar AS, Harris H, Jacobs E, Bumpus-White P, Balbuena R, Stambaugh H, Crayton K, Haynie J, Quintero Ilutsik J, Longo C, Bergman Y, Singh S, Murray M, Sabour S, Robinson ML, Machado M-J, Simner PJ.   +16 more
europepmc   +1 more source

Ceftazidime-avibactam resistance evolution in <i>Pseudomonas aeruginosa</i> and implications for cross-resistance to other novel β-lactams. [PDF]

Antimicrob Agents Chemother
Dorazio AJ, Kline EG, Squires KM, Shah S, Van Tyne D, Wu JY, Pogue JM, Shields RK.   +7 more
europepmc   +1 more source

Ceftazidime-Avibactam as Early Empiric Therapy for Gram-Negative Nosocomial Infections: A Risk-Stratified Empiric Use Informed by National AMR Surveillance Data 2024. [PDF]

Antibiotics (Basel)
Subhi A, Subhi R, Sattar Y, Alshamsi S, Abdulrazzaq N, Chhabrani P.   +5 more
europepmc   +1 more source

Resistance development in KPC-producing <i>Klebsiella pneumoniae</i> under ceftazidime/avibactam-meropenem pressure: KPC-2 Ω-loop mutations attenuate avibactam efficacy. [PDF]

Microbiol Spectr
Li F-H, Zheng M, Zhong G-M, He X-M, Hu M-Z, Kuang X, Wu J-J, Li C-M, Wang J-N, Zhou X-Y, Yu Y.   +10 more
europepmc   +1 more source